At BIOTYPE we pave the way for our customers to succeed!

Share this post

Cardiovascular diseases (CVD) lead to serious burdens for those affected, and for the healthcare system. Annually, the European Union registers over six million cases and 1.8 million deaths in CVDs with costs of around €210 billion, exceeding the European yearly economy.

The development of new precise RNA therapeutic approaches, that can alter levels of non-coding RNAs to restore their normal levels and functions within pathological processes of cardiac diseases, is the goal of Cardior Pharmaceuticals.

Consistent measurements of micro-RNA levels as an indicator of the target engagement and the compound’s mechanism of action following treatment in clinical trials and across all clinical trial centers is a critical prerequisite for all phases of therapy development.

The CardiorHealth miR-132 PCR kit is the first CE marked PCR kit designed to monitor the treatment with a non-coding RNA-based therapeutic. Check out the full press release of Cardior and learn more about the therapeutic potential of blocking aberrant levels of miR-132 on their website.

We are extremely proud that our biomarker assay development and manufacturing services have contributed to this success, and we look forward to continuing our cooperation with Cardior Pharmaceuticals.